{"id":116437,"date":"2009-09-01T00:00:00","date_gmt":"2009-09-01T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/report\/fforxx0409-marketaccess-formulary-advantages-in-osteoporosis-rise-and\/"},"modified":"2009-09-01T00:00:00","modified_gmt":"2009-09-01T00:00:00","slug":"fforxx0409-marketaccess-formulary-advantages-in-osteoporosis-rise-and","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/fforxx0409-marketaccess-formulary-advantages-in-osteoporosis-rise-and\/","title":{"rendered":"Formulary Advantages in Osteoporosis: Rise and Fall of Access in the Wake of Fosamax Generics, Rebate and Contracting Efforts, and New Drug Launches"},"content":{"rendered":"<p>With 62 million cases of osteoporosis and osteopenia in the United States and a U.S. market of over $3.8 billion, few brands are competing for a very large<br \/>\nappropriation of healthcare dollars. Major brands, however, now have to contend<br \/>\nwith generic alendronate (Merck\u2019s Fosamax, generics) and convince payers that<br \/>\ntheir brand provides a sufficient value proposition for Tier 2 reimbursement. More<br \/>\nrecently, the osteoporosis market in the United States has seen growing<br \/>\nuncertainty as Amgen\u2019s Prolia (denosumab) received a favorable ruling from an<br \/>\nFDA advisory panel, and Eli Lilly announced discontinuation of Phase III<br \/>\nclinical development of arzoxifene.<\/p>\n<p>Using tiering and restrictions data from Fingertip Formulary,<br \/>\nas well as insight from 50 pharmacy directors, this report determines the key<br \/>\ntrends in reimbursement in osteoporosis, drivers of these trends, and how<br \/>\nstakeholders can capitalize on future shifts in coverage to steal share from<br \/>\nthe competition.<\/p>\n","protected":false},"template":"","class_list":["post-116437","report","type-report","status-publish","hentry","report-gateway-marketaccess","marketaccess-date-549"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/116437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":0,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/116437\/revisions"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=116437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}